Simulect 20 mg
Simulect 20 mg is a medicine authorised by Swissmedic under authorisation number 54630. The authorisation holder is Novartis Pharma Schweiz AG. The medicinal product code is Biotechnological medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 07 April 1998 and the authorisation is valid without a time limit. ATC code L04AC02 places the medicine in the group Immunosuppressants.
| Authorisation number | 54630 |
|---|---|
| Name | Simulect 20 mg |
| Full name | Simulect 20 mg, Pulver und Lösungsmittel zur Herstellung einer Injektions-/Infusionslösung |
| Authorisation holder | Novartis Pharma Schweiz AG |
| Medicinal product code | Biotechnological medicines |
| Dispensing category | B · Prescription only |
| ATC code | L04AC02 |
| First authorisation | 07 April 1998 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Simulect 20 mg, Pulver und Lösungsmittel zur Herstellung einer Injektions-/Infusionslösung | B | 07 April 1998 |
| 2 | Simulect 10 mg, Pulver und Lösungsmittel zur Herstellung einer Injektions-/Infusionslösung | B | 27 March 2003 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 18 | 1 + 1 | Ampulle(n) | L04AC02 | 07.15.0. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Simulect 20 mg authorised in Switzerland?
Yes. Simulect 20 mg is authorised by Swissmedic under authorisation number 54630, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Simulect 20 mg have?
Simulect 20 mg is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Simulect 20 mg?
The authorisation holder is Novartis Pharma Schweiz AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.